Lv41
660 积分 2022-04-12 加入
513 Trial in progress: phase 1 first-in-human study of XL092 administered alone or in combination with immune checkpoint inhibitors in patients with inoperable locally advanced or metastatic solid tumors
5个月前
已完结
481P A phase I first-in-human study of XL092 in patients (pts) with locally advanced or metastatic solid tumors: Results from dose-escalation of XL092 alone and in combination with atezolizumab
5个月前
已完结
Degrader–Antibody Conjugates: Emerging New Modality
5个月前
已完结
The New Frontier: Merging Molecular Glue Degrader and Antibody–Drug Conjugate Modalities To Overcome Strategic Challenges
5个月前
已完结
Clinical development success rates for investigational drugs
8个月前
已完结
Long-term Efficacy and Safety of Elamipretide in Patients with Barth Syndrome: 168-Week Open-label Extension Results of TAZPOWER
1年前
已完结
Adjuvant Gemcitabine Plus Cisplatin and Chemoradiation in Patients With Gallbladder Cancer
1年前
已完结
Dendritic Cell–Based Immunotherapy in Patients With Resected Pancreatic Cancer
1年前
已完结
Multicenter phase I/II trial of gemcitabine, oxaliplatin and nab-paclitaxel as first-line treatment for patients with advanced biliary tract cancer
1年前
已完结
Urinary bother, Urinalysis, and Two-Year Efficacy Follow-Up Results of Phase I trial of intravesical Bacillus Calmette-Guérin combined with intravenous pembrolizumab in recurrent or persistent high-grade non-muscle-invasive bladder cancer after previous Bacillus Calmette-Guérin treatment
1年前
已完结
皖公网安备34019202002308
